Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

This study has been terminated.
(Low enrollment rate)
Sponsor:
Collaborator:
Immutep S.A.
Information provided by (Responsible Party):
Prof Olivier Michielin, M.D., Ph.D., Centre Hospitalier Universitaire Vaudois
ClinicalTrials.gov Identifier:
NCT01308294
First received: March 3, 2011
Last updated: October 14, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2014
  Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)